Meeting
2016 ASCO Annual Meeting
Phase I dose-escalation and pharmacokinetic (PK) study of regorafenib in pediatric patients with recurrent or refractory solid malignancies.
Authors
Birgit Geoerger
Gustave Roussy, Villejuif, France
Birgit Geoerger , Bruce Morland , Irene Jimenez , Didier Frappaz , Andrew DJ Pearson , Gilles Vassal , Patricia Maeda , Jasmine Kincaide , Udo Mueller , Sarah Schlief , Adriaan Cleton , Andrea Chassot-Agostinho , Lynley V Marshall
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT02085148
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10542)
DOI
10.1200/JCO.2016.34.15_suppl.10542
Abstract #
10542
Poster Bd #
233
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
ADVL1513: Results of a phase 1 trial of entinostat, an oral histone deacetylase inhibitor, in pediatric patients with recurrent or refractory solid tumors.
First Author: Suman Malempati
Poster
2021 ASCO Annual Meeting
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).
First Author: Jennifer Foster
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer
Poster
2014 ASCO Annual Meeting
A phase I study of cabozantinib (XL184) in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: A Children’s Oncology Group phase I consortium trial.
First Author: Meredith K. Chuk